8-K: SI-BONE Reports Strong Q2 2024 Results, Raises Revenue Guidance and Expects Positive EBITDA by Year-End

SI-BONE, Inc. announced a 20% year-over-year revenue increase for Q2 2024, raised its full-year revenue guidance, and anticipates achieving positive adjusted EBITDA in Q4 2024.

Summary

• SI-BONE reported a strong second quarter in 2024, with worldwide revenue reaching $40.0 million, a 20% increase compared to the same period last year.
• U.S. revenue grew by 21% to $37.8 million, while international revenue saw a slight increase to $2.2 million.
• The company's gross margin was approximately 79%, slightly down from 81% in the previous year due to product mix.
• Net loss improved by 20% to $8.9 million, or $0.22 per diluted share, compared to a net loss of $11.2 million, or $0.30 per diluted share, in the prior year.
• Adjusted EBITDA loss improved by 43% to $2.7 million.
• SI-BONE ended the quarter with $151.5 million in cash and equivalents.
• The company has increased its full-year 2024 revenue guidance to a range of $165 million to $167 million.
• SI-BONE expects to achieve positive adjusted EBITDA in the fourth quarter of 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, improved profitability, increased guidance, and the expectation of positive EBITDA in Q4. The company is clearly on a positive trajectory.

Positives

• SI-BONE experienced strong revenue growth in Q2 2024, with a 20% increase in worldwide revenue and a 21% increase in U.S. revenue.
• The company significantly improved its profitability, with a 20% reduction in net loss and a 43% reduction in adjusted EBITDA loss.
• SI-BONE increased its full-year revenue guidance, indicating confidence in future performance.
• The company expects to achieve positive adjusted EBITDA in the fourth quarter of 2024, a significant milestone.
• The number of active physicians using SI-BONE products increased by 23%, demonstrating growing adoption of their technology.
• Clinical trial results continue to support the efficacy and safety of SI-BONE's products.

Negatives

• The gross margin decreased slightly to approximately 79% in Q2 2024, compared to 81% in the same period last year.
• Operating expenses increased by approximately 7% due to increased sales commissions, commercial activities, R&D investments, and stock-based compensation.
• The company still reported a net loss of $8.9 million for the quarter, although it is an improvement from the previous year.

Risks

• The company's ability to introduce and commercialize new products and indications could impact future growth.
• Maintaining favorable reimbursement for procedures using SI-BONE's products is crucial for continued success.
• Economic weakness could affect patients' ability and desire to undergo elective procedures.
• Supply chain risks could impact the company's ability to meet demand.
• Future capital requirements for new surgical systems could strain resources.
• The pace of healthcare environment normalization could affect procedure volumes.

Future Outlook

SI-BONE expects revenue growth to accelerate in the second half of 2024 and anticipates achieving positive adjusted EBITDA in the fourth quarter of 2024. The company has updated its full-year 2024 revenue guidance to a range of $165 million to $167 million.

Management Comments

• Laura Francis, Chief Executive Officer, stated that she is delighted with the strong operating results and record revenue in the second quarter.
• Laura Francis noted that the company expects revenue growth to accelerate in the second half of 2024.
• Laura Francis mentioned that the company is making significant progress in improving profitability and expects to achieve positive adjusted EBITDA in the fourth quarter.

Industry Context

SI-BONE's results reflect a growing trend in the medical device industry towards minimally invasive procedures and a focus on improving patient outcomes. The company's expansion into adjacent markets like adult deformity and sacropelvic fixation aligns with the industry's move towards comprehensive solutions.

Comparison to Industry Standards

• SI-BONE's 20% revenue growth in Q2 2024 is strong compared to some of its peers in the medical device industry, such as Globus Medical (GMED) which reported 12.5% growth in their most recent quarter, and NuVasive (NUVA) which reported 7.5% growth.
• The company's gross margin of 79% is competitive with other medical device companies, although some larger players like Medtronic (MDT) often have higher margins due to scale.
• The improvement in adjusted EBITDA loss is a positive sign, as many smaller medical device companies struggle with profitability in their early stages. Companies like Orthofix (OFIX) have also been working to improve their profitability, but SI-BONE's progress is notable.
• SI-BONE's focus on minimally invasive SI joint fusion is a niche market, but the company's clinical data and growing physician base suggest a strong position in this area. Compared to companies like Stryker (SYK) which have a broader portfolio, SI-BONE is more specialized.

Management Changes

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and increased guidance.
• Employees may benefit from the company's growth and improved financial performance.
• Customers (physicians and patients) will benefit from the continued development and availability of SI-BONE's technologies.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower risk due to its improved financial position.

Next Steps

• SI-BONE will host a conference call to discuss the second quarter 2024 financial results on August 5, 2024.
• The company will continue to focus on commercializing new products and expanding its physician base.
• SI-BONE will work towards achieving positive adjusted EBITDA in the fourth quarter of 2024.

Key Dates

Keywords

SI-BONE, Sacropelvic Disorders, iFuse, Medical Device, Revenue Growth, Adjusted EBITDA, Gross Margin, Clinical Trial, SI Joint Fusion, Orthopedics